![]() In contrast, risk-based monitoring (RBM) makes use of central computerized review of clinical trial data and site metrics to determine if and when clinical sites should receive more extensive quality review or intervention. On-site review is time consuming, expensive (estimated at up to a third of the cost of a clinical trial), prone to error, and limited in its ability to provide insight for data trends across time, patients, and clinical sites. Traditional interpretation of this guidance for pharmaceutical trials has led to extensive on-site monitoring, including 100% source data verification. International guidelines recommend that clinical trial data should be actively reviewed or monitored the well-being of trial participants and the validity and integrity of the final analysis results are at stake. ![]() ![]() Improve efficiency while reducing costs in clinical trials with centralized monitoring techniques using JMP and SAS.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |